נולוג'יקס 250 מ"ג

Country: Իսրայել

language: եբրայերեն

source: Ministry of Health

active_ingredient:

BELATACEPT 25 MG/ML

MAH:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

ATC_code:

L04AA28

pharmaceutical_form:

POWDER FOR CONCENTRATE FOR INFUSION

administration_route:

I.V

manufactured_by:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

therapeutic_group:

BELATACEPT

therapeutic_indication:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

authorization_date:

2012-08-01